Creo Medical Group PLC Directorate Change (0488S)
06 July 2020 - 4:00PM
UK Regulatory
TIDMCREO
RNS Number : 0488S
Creo Medical Group PLC
06 July 2020
Creo Medical Group plc
("Creo" or the "Company")
Directorate Change, Appointment of Chief Commercial Officer to
the Board
&
Further strengthening of Senior Management team
Creo Medical Group plc (AIM: CREO), the medical device company
focused on the emerging field of surgical endoscopy, announces the
following change to the Board and strengthening of the Senior
Management team.
Appointment of David Woods as Executive Director (previously
Non-Exec)
David Woods, Non-Executive Director, has been appointed as Chief
Commercial Officer ('CCO'), with effect from 1 August 2020. David
has extensive experience in the med-tech sector and joins the
Company in his new full-time executive role based in the USA,
having previously been the President and CEO of PENTAX Americas and
M&A Director of HOYA Group PENTAX Medical.
David's experience in the Medical Device Market encompasses
Gastroenterology, General and Orthopaedic Surgery, Pulmonology and
Ear Nose and Throat. Alongside this, David's significant operating
experience, market understanding, and proven track record of
achievement will benefit the Creo team at a crucial time when the
Company is moving from early clinical adoption to global
commercialisation expansion. As CCO, David will provide leadership
and strategic direction for Creo's Group Commercial divisions
overseeing all strategic global commercial activities, which are
key to Creo's growth.
For further details on David's experience see here:
https://investors.creomedical.com/about-us/board-of-directors
Further Senior Management Appointments
As the Company prepares to accelerate and progress commercially,
a President of Sales, Service and Commercial Operations has also
been appointed in both the USA and the Asia-Pacific regions to
provide a substantial presence, gain market share and revenue
within these regions, and give healthcare professionals access to
much needed advanced medical technologies and instruments. These
appointments, along with other recent appointments, bring with them
experience from companies such as Medtronic, Covidien, BARRX,
J&J, Pentax, Philips Healthcare, US Endoscopy, and BTG
Group.
Creo has also made further senior appointments for US Sales,
Service and Commercial operations, Wider EMEA Sales, Global
Marketing and Product Management, including marketing
communications, Clinical professionals, and Professional Education.
The Company is looking to grow the US based team for market and
sales development as well as increase the UK based team for
business management coverage throughout the UK and EU, and for the
key delivery of sales and service operations in all regions. The
future growth of the Clinical programme will also provide further
recruitment opportunities to expand the clinical team and ensure
that clinicians on a global scale are trained in the use of Creo's
full suite of devices.
David Woods commented: "I am very fortunate to have worked with
a company as great as PENTAX Medical for more than two decades and
to have worked with such terrific people. It is certainly an
experience where I have learned so much. Making the decision to
leave was incredibly difficult, but I am enormously excited by the
opportunity that Creo presents as we see increased commercial
momentum from Creo's first products and the commercial launch of a
wider suite of medical devices that will radically change the way
endoscopists and surgeons treat patients worldwide."
Craig Gulliford, CEO of Creo, commented: "Dave has been working
with Creo since 2015 and we are delighted that he will be joining
us full-time as Chief Commercial Officer, during a key phase in the
Company's development as we look to commercialise our wider range
advanced energy products. Dave brings with him a wealth of
experience in the med-tech sector having been a key driver of the
PENTAX Medical Americas team for more than 20 years. Dave has been
a great support as a Non-Executive and his decision to join us
full-time speak volumes for the commercial opportunity we have
before us across multiple applications for our technology. Despite
the COVID-19 climate, over the last six months we have been able to
attract some terrific commercial talent in addition to Dave joining
full time. These senior management additions are fundamental as we
expand our commercialisation and come at an exciting time as we
launch a range of innovative devices to improve patient outcomes
globally."
Enquires:
Creo Medical Group plc www.creomedical.com
Richard Rees (CFO) +44 (0)1291 606 005
Cenkos Securities plc +44 (0)20 7397 8900
Stephen Keys / Cameron MacRitchie
(NOMAD)
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: +44 (0)7980 541 893 / +44 (0)7515
909 238
About Creo Medical
Creo Medical, founded in 2003, is a medical device company
focused on the development and commercialisation of minimally
invasive surgical devices, by bringing advanced energy to
endoscopy. The Company's mission is to improve patient outcomes by
applying microwave and RF energy to surgical endoscopy. Creo has
developed CROMA, an electrosurgical Advanced Energy Platform that
combines bipolar radiofrequency for precise localised cutting and
microwave for controlled coagulation. This technology provides
clinicians with flexible, accurate and controlled surgical
solutions.
The Company's strategy is to bring its CROMA Advanced Energy
Platform powered by unique full spectrum adaptive technology to
market enabling a suite of medical devices which the Company has
designed, initially for the emerging field of GI therapeutic
endoscopy, an area with high unmet needs. The CROMA Advanced Energy
platform will be developed further for bronchoscopy and laparoscopy
procedures. The Company believes its technology can impact the
landscape of surgery and endoscopy by providing a safer,
less-invasive and more cost-efficient option of treatment.
For more information about Creo Medical please see our website,
www.creomedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOABLGDRIUGDGGX
(END) Dow Jones Newswires
July 06, 2020 02:00 ET (06:00 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2024 to May 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From May 2023 to May 2024